These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 36613689)
21. Oxidative stress as a possible mechanism of statin-induced myopathy. Ahmadi Y; Ghorbanihaghjo A; Naghi-Zadeh M; Yagin NL Inflammopharmacology; 2018 Jun; 26(3):667-674. PubMed ID: 29574631 [TBL] [Abstract][Full Text] [Related]
22. Coenzyme Q10 and statin-related myopathy. Drug Ther Bull; 2015 May; 53(5):54-6. PubMed ID: 25977402 [TBL] [Abstract][Full Text] [Related]
23. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397 [TBL] [Abstract][Full Text] [Related]
24. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Golightly LK; Barber GR; Barron MA; Page RL Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530 [TBL] [Abstract][Full Text] [Related]
26. Excessive expression of miR-1a by statin causes skeletal injury through targeting mitogen-activated protein kinase kinase kinase 1. Fu CN; Song JW; Song ZP; Wang QW; Bai WW; Guo T; Li P; Liu C; Wang SX; Dong B Aging (Albany NY); 2021 Apr; 13(8):11470-11490. PubMed ID: 33864447 [TBL] [Abstract][Full Text] [Related]
27. Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts. Emelyanova L; Sra A; Schmuck EG; Raval AN; Downey FX; Jahangir A; Rizvi F; Ross GR ESC Heart Fail; 2019 Oct; 6(5):1027-1040. PubMed ID: 31520523 [TBL] [Abstract][Full Text] [Related]
28. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999 [TBL] [Abstract][Full Text] [Related]
29. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Ramakumari N; Indumathi B; Katkam SK; Kutala VK Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243 [TBL] [Abstract][Full Text] [Related]
30. Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Kang JH; Nguyen QN; Mutka J; Le QA J Pharm Pract; 2017 Oct; 30(5):521-527. PubMed ID: 27798247 [TBL] [Abstract][Full Text] [Related]
31. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554 [TBL] [Abstract][Full Text] [Related]
32. Clinical features related to statin-associated muscle symptoms. Ochs-Balcom HM; Nguyen LM; Ma C; Isackson PJ; Luzum JA; Kitzmiller JP; Tarnopolsky M; Weisman M; Christopher-Stine L; Peltier W; Wortmann RL; Vladutiu GD Muscle Nerve; 2019 May; 59(5):537-543. PubMed ID: 30549046 [TBL] [Abstract][Full Text] [Related]